Stryker Shares Outstanding 2006-2018 | SYK
Current and historical number of shares outstanding for Stryker (SYK) from 2006 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
| Stryker Annual Shares Outstanding (Millions of US $) |
|
|---|---|
| 2017 | $380 |
| 2016 | $379 |
| 2015 | $381 |
| 2014 | $383 |
| 2013 | $382 |
| 2012 | $383 |
| 2011 | $390 |
| 2010 | $400 |
| 2009 | $399 |
| 2008 | $414 |
| 2007 | $417 |
| 2006 | $412 |
| 2005 | $411 |
| Stryker Quarterly Shares Outstanding (Millions of US $) |
|
|---|---|
| Q2 2018 | $380 |
| Q1 2018 | $381 |
| Q4 2017 | $380 |
| Q3 2017 | $380 |
| Q2 2017 | $380 |
| Q1 2017 | $379 |
| Q4 2016 | $379 |
| Q3 2016 | $379 |
| Q2 2016 | $379 |
| Q1 2016 | $377 |
| Q4 2015 | $381 |
| Q3 2015 | $381 |
| Q2 2015 | $381 |
| Q1 2015 | $384 |
| Q4 2014 | $383 |
| Q3 2014 | $383 |
| Q2 2014 | $383 |
| Q1 2014 | $383 |
| Q4 2013 | $382 |
| Q3 2013 | $382 |
| Q2 2013 | $381 |
| Q1 2013 | $383 |
| Q4 2012 | $383 |
| Q3 2012 | $383 |
| Q2 2012 | $383 |
| Q1 2012 | $384 |
| Q4 2011 | $390 |
| Q3 2011 | $388 |
| Q2 2011 | $392 |
| Q1 2011 | $394 |
| Q4 2010 | $400 |
| Q3 2010 | $398 |
| Q2 2010 | $399 |
| Q1 2010 | $400 |
| Q4 2009 | $399 |
| Q3 2009 | $400 |
| Q2 2009 | $399 |
| Q1 2009 | $399 |
| Q4 2008 | $414 |
| Q3 2008 | $416 |
| Q2 2008 | $418 |
| Q1 2008 | $418 |
| Q4 2007 | $417 |
| Q3 2007 | $418 |
| Q2 2007 | $417 |
| Q1 2007 | $416 |
| Q4 2006 | $412 |
| Q3 2006 | $412 |
| Q2 2006 | $411 |
| Q1 2006 | $411 |
| Q4 2005 | $411 |
| Q3 2005 | $411 |
| Q2 2005 | $411 |
| Q1 2005 | $411 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $62.038B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $122.465B | 18.95 |
| Abbott Laboratories (ABT) | United States | $112.329B | 23.54 |
| Boston Scientific (BSX) | United States | $46.397B | 24.14 |
| Baxter (BAX) | United States | $38.200B | 26.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.941B | 16.02 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.395B | 0.00 |
| ResMed (RMD) | United States | $15.384B | 30.53 |
| Perrigo (PRGO) | Ireland | $9.565B | 13.57 |
| Bio-Rad Laboratories (BIO) | United States | $9.531B | 61.26 |
| Hill-Rom Holdings (HRC) | United States | $6.308B | 21.40 |
| Canopy Growth (CGC) | Canada | $6.230B | 0.00 |
| ICU Medical (ICUI) | United States | $5.941B | 40.56 |
| Haemonetics (HAE) | United States | $5.156B | 47.05 |
| Insulet (PODD) | United States | $5.134B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.432B | 0.00 |
| Hutchison China MediTech (HCM) | China | $4.374B | 0.00 |
| Neogen (NEOG) | United States | $4.327B | 68.95 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.748B | 0.00 |
| National Vision Holdings (EYE) | United States | $3.382B | 0.00 |
| NuVasive (NUVA) | United States | $3.320B | 31.49 |
| Quidel (QDEL) | United States | $2.722B | 55.76 |
| Phibro Animal Health (PAHC) | United States | $1.978B | 29.37 |
| NxStage Medical (NXTM) | United States | $1.856B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.252B | 752.80 |
| Eagle Pharmaceuticals (EGRX) | United States | $1.195B | 35.26 |
| AtriCure (ATRC) | United States | $1.103B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.075B | 17.57 |
| OraSure Technologies (OSUR) | United States | $1.025B | 67.04 |
| Orthofix (OFIX) | United States | $1.012B | 30.83 |
| TG Therapeutics (TGTX) | United States | $0.981B | 0.00 |
| Cerus (CERS) | United States | $0.958B | 0.00 |
| Surmodics (SRDX) | United States | $0.941B | 113.63 |
| MacroGenics (MGNX) | United States | $0.901B | 0.00 |
| Owens & Minor (OMI) | United States | $0.879B | 9.41 |
| Omeros (OMER) | United States | $0.861B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.706B | 33.87 |
| PetIQ (PETQ) | United States | $0.665B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.636B | 21.74 |
| Insys Therapeutics (INSY) | United States | $0.554B | 0.00 |
| Evolus (EOLS) | United States | $0.554B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.502B | 15.60 |
| NanoString Technologies (NSTG) | United States | $0.417B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.363B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.340B | 21.90 |
| BioLife Solutions (BLFS) | United States | $0.325B | 0.00 |
| Quanterix (QTRX) | United States | $0.323B | 0.00 |
| Surface Oncology (SURF) | United States | $0.287B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.244B | 0.00 |
| Chimerix (CMRX) | United States | $0.210B | 0.00 |
| Fonar (FONR) | United States | $0.169B | 10.25 |
| Chembio Diagnostics (CEMI) | United States | $0.162B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.122B | 0.00 |
| Female Health (VERU) | United States | $0.117B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.093B | 27.88 |
| United-Guardian (UG) | United States | $0.086B | 18.95 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.083B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.077B | 0.00 |
| Neurotrope (NTRP) | United States | $0.076B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.065B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.038B | 0.00 |
| ImmuCell (ICCC) | United States | $0.036B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.032B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.026B | 0.00 |
| Senestech (SNES) | United States | $0.018B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.007B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.003B | 0.00 |
